Drugs / 111In-ABD147
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07052760 | Apr 2026 → May 2028 | castration-resistant prostate carcinoma, neuroendocrine neoplasm | Thomas Hope | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 111In-ABD147 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07052760 ↗ |
| Modality | Monoclonal antibody | “to create an antibody (VHH-Fc)” NCT07052760 ↗ |
| Route | Intravenous | “Given intravenously (IV) prior to imaging” NCT07052760 ↗ |
| Target | DLL3 | “Delta-like ligand 3 (DLL3) antigen binding domain” NCT07052760 ↗ |